Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study Abstract #2257

Introduction: Neuroendocrine carcinomas (NEC) of the colon and rectum are aggressive and rare tumours. The Digestive Tract WHO classification 2010 defines the entity of large cell NEC (LCNEC) in contrast to small cell NEC (SCNEC).
Aim(s): This study provides a meticulous characterization of LCNEC with regard to clinicopathological aspects.
Materials and methods: Over a period of four years 455 patients with colorectal cancer (CRC) have been undergone surgery in two huge tumour centers. After immunhistochemical staining with specific neuroendocrine markers they have been subdivided in three subgroups of high grade neuroendocrine neoplasms (high grade NEN): LCNEC, SCNEC and mixed adenoneuroendocrine carcinomas (MANEC). These were further characterized by 16 immunohistochemical stains and molecular markers.
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Inga Boeck

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1551 Establishment and Characterization of Three GEP-NEC Cell Lines for In Vitro and In Vivo Studies
Introduction: To date chemotherapeutic concepts applying cisplatin/etoposide for the treatment of highly aggressive GEP-NEC do not provide convincing results. Thus, there is an urgent need for NEC cell line models that provide a reliable experimental system in identifying novel therapeutic targets.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Andreas Krieg
Authors: Krieg A, Riemer J C, Dizdar L, Mersch S, ...
Keywords: GEP-NEC
#1204 Clinico-Pathologic and Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)
Introduction: GEP-NECs show Ki67>20% and/or >20 mitoses x10 HPF. Mixed AdenoNeuroendocrine Carcinomas (MANECs) are mixed exocrine-neuroendocrine neoplasms. NECs are associated with poor prognosis but recent findings have suggested that there is a fraction of patients showing a better than expected survival rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: NEC, Ki67, MANEC, PROGNOSIS
#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?
Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Jules Derks
Keywords: lcnec, chemotherapy, nec, lung
#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Alberto Bongiovanni
Keywords: GEP-NEC, chemotherapy
#2151 Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis
Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Professor Vincenzo Adamo